{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T02:29:39Z","timestamp":1772418579909,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T00:00:00Z","timestamp":1521417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Oritavancin is a lipoglycopeptide used in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults. To characterize its use in patients in the postapproval setting, a patient registry was developed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data collected in an ongoing retrospective observational registry are used to evaluate the utilization, outcomes, and adverse events (AEs) associated with oritavancin for the treatment of infections presumed or confirmed to be caused by gram-positive (GP) bacteria in clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Data for 112 patients from 8 sites were collected. All patients received a single 1200-mg dose of oritavancin mostly in an infusion center. Infection type included cellulitis (67.0%), cutaneous abscess (21.4%), and wound (4.5%). Most patients (72.3%) received 1 or more antimicrobial agents for the index GP infection within 28 days prior to oritavancin treatment. Of positive cultures obtained prior to oritavancin administration, methicillin-resistant Staphylococcus aureus was the predominant pathogen (78.4%). A positive clinical response was observed in 92.8% of patients, and microbial eradication was observed in 90.0% of patients with post-therapy cultures. Within 28 days following oritavancin administration, 4 (3.6%) patients were hospitalized for failure of treatment of the index infection. Five (4.5%) patients experienced 1 or more possible drug-related AEs, which were consistent with types previously reported. There were no drug-related serious AEs reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Clinical and microbiologic outcomes and safety of single-dose oritavancin 1200 mg were similar in this older patient population with multiple comorbid conditions to those observed in the phase 3 SOLO trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofy051","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T04:32:55Z","timestamp":1521433975000},"source":"Crossref","is-referenced-by-count":17,"title":["A Real-world Patient Registry for Oritavancin Demonstrates Efficacy and Safety Consistent With the Phase 3 SOLO Program"],"prefix":"10.1093","volume":"5","author":[{"given":"Mark","family":"Redell","sequence":"first","affiliation":[{"name":"The Medicines Company, Parsippany, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Moeck","sequence":"additional","affiliation":[{"name":"The Medicines Company, St. Laurent, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Lucasti","sequence":"additional","affiliation":[{"name":"South Jersey Infectious Diseases, Somers Point, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Durso","sequence":"additional","affiliation":[{"name":"The Medicines Company, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Kennedy","sequence":"additional","affiliation":[{"name":"The Medicines Company, Parsippany, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Fusaro","sequence":"additional","affiliation":[{"name":"The Medicines Company, Parsippany, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeff","family":"Loutit","sequence":"additional","affiliation":[{"name":"The Medicines Company, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Dudley","sequence":"additional","affiliation":[{"name":"The Medicines Company, San Diego, California"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,3,19]]},"reference":[{"key":"2020081004275004500_CIT0001","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"2020081004275004500_CIT0002","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020081004275004500_CIT0003","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2016.07.019","article-title":"Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus","volume":"48","author":"Corey","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004275004500_CIT0004","volume-title":"Prescribing Information \u2013 ORBACTIV (Oritavancin) for Injection","author":"The Medicines Company"},{"key":"2020081004275004500_CIT0005","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081004275004500_CIT0006","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1001\/archinternmed.2011.29","article-title":"Decreased antibiotic utilization after implementation of a guideline for inpatient cellulitis and cutaneous abscess","volume":"171","author":"Jenkins","year":"2011","journal-title":"Arch Intern Med"},{"key":"2020081004275004500_CIT0007","volume-title":"Antibiotic resistance patient safety atlas","author":"Centers for Disease Control and Prevention"},{"key":"2020081004275004500_CIT0008","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40121-017-0146-1","article-title":"Infections in cancer patients with solid tumors: a review","volume":"6","author":"Rolston","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2020081004275004500_CIT0009","doi-asserted-by":"crossref","first-page":"ofw274","DOI":"10.1093\/ofid\/ofw274","article-title":"Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials","volume":"4","author":"Lodise","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2020081004275004500_CIT0010","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-016-0145-7","article-title":"Single-dose oritavancin compared to standard of care IV antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study","volume":"6","author":"Anastasio","year":"2017","journal-title":"Infect Dis Ther"},{"key":"2020081004275004500_CIT0011","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1128\/AAC.02626-15","article-title":"Relationship between adherence to oral antibiotics and postdischarge clinical outcomes among patients hospitalized with Staphylococcus aureus skin infections","volume":"60","author":"Eells","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004275004500_CIT0012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clinthera.2015.11.014","article-title":"Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations","volume":"38","author":"Lodise","year":"2016","journal-title":"Clin Ther"},{"key":"2020081004275004500_CIT0013","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40261-015-0365-8","article-title":"Use of oritavancin in acute bacterial skin and skin structure infections patients receiving intravenous antibiotics: a US hospital budget impact analysis","volume":"36","author":"Jensen","year":"2016","journal-title":"Clin Drug Investig"},{"key":"2020081004275004500_CIT0014","volume-title":"Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment","author":"US Food and Drug Administration. Guidance for Industry"},{"key":"2020081004275004500_CIT0015","article-title":"Time to onset and duration of adverse events in patients with acute bacterial skin and skin structure infection treated with oritavancin \u2013 the SOLO studies","author":"Corey"},{"key":"2020081004275004500_CIT0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1871526517666161108130148","article-title":"Use of oritavancin (novel new lipoglycopeptide) in the treatment of prosthetic joint infections (PJI): a possible alternative novel approach to a difficult problem","volume":"17","author":"Antony","year":"2017","journal-title":"Infect Disord Drug Targets"},{"key":"2020081004275004500_CIT0017","doi-asserted-by":"crossref","first-page":"ofv156","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2020081004275004500_CIT0018","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-world experience with oritavancin therapy in invasive gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect Dis Ther"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/6\/ofy051\/33576272\/ofy051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/5\/6\/ofy051\/33576272\/ofy051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:29:11Z","timestamp":1597048151000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofy051\/4942456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,19]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofy051","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,3,19]]},"article-number":"ofy051"}}